BioSpace News Archive

Stoke Therapeutics, Inc. today announced that management will present at the 21st Annual Needham Virtual Healthcare Conference on Tuesday, April 12, 2022, at 8:00 a.m. ET.

Medivir AB (Nasdaq Stockholm: MVIR) today announces that the Annual Report for 2021 now is available at the company’s website: www.medivir.com.

AIVITA Biomedical, Inc. today announced the appointment of distinguished neuroscientist and industry specialist H. Christian Fibiger, Ph.D. to its board of directors.

Inspire Medical Systems, Inc. (NYSE: INSP) (“Inspire”), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, today announced that it will release financial results for the first quarter 2022 after the close of trading on Tuesday, May 3.

electroCore, Inc. announced it has entered into an agreement with Teijin Limited, a global conglomerate based in Japan offering advanced solutions in the fields including healthcare, material and information technology, to license certain exclusive rights to its non-invasive vagus nerve stimulation technology for commercialization in Japan for a range of primary headache disorders.

PepGen, Inc., a company developing the next generation of oligonucleotide therapeutics with the goal of transforming the treatment of severe neuromuscular and neurologic diseases, announced that it has appointed Michelle Mellion, M.D., as Senior Vice President, Head of Clinical Development.

MiMedx Group, Inc., a transformational placental biologics company, announced it will sponsor a lunch symposium at the Symposium on Advanced Wound Care Spring on April 6-10 in Phoenix, Arizona.

VBI Vaccines Inc. today announced updated clinical and preclinical data from its coronavirus program, VBI-2900.

858 Therapeutics today announced the strengthening of its board of directors and leadership team in preparation for its next stage of growth.

CUTERA, INC. today announced that the first patient outside of clinical trials was treated with AviClear, the only device cleared by the FDA for the treatment of mild, moderate, and severe acne.